untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:23:12Z</responseDate>
<request identifier=oai:HAL:hal-01217989v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-01217989v1</identifier>
<datestamp>2018-01-11</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:CNRS</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:UNIV-ANGERS</setSpec>
<setSpec>collection:UNIV-PARIS7</setSpec>
<setSpec>collection:UNIV-BREST</setSpec>
<setSpec>collection:HCL</setSpec>
<setSpec>collection:UPMC</setSpec>
<setSpec>collection:IRSET</setSpec>
<setSpec>collection:APHP</setSpec>
<setSpec>collection:UNIV-NANTES</setSpec>
<setSpec>collection:UNIV-RENNES1</setSpec>
<setSpec>collection:UNIV-PARIS5</setSpec>
<setSpec>collection:IMMUNO</setSpec>
<setSpec>collection:IRSET-CCII</setSpec>
<setSpec>collection:IFR140</setSpec>
<setSpec>collection:BIOSIT</setSpec>
<setSpec>collection:UR1-UFR-SVE</setSpec>
<setSpec>collection:INSERM</setSpec>
<setSpec>collection:USPC</setSpec>
<setSpec>collection:HL</setSpec>
<setSpec>collection:UR1-HAL</setSpec>
<setSpec>collection:EHESP</setSpec>
<setSpec>collection:STATS-UR1</setSpec>
<setSpec>collection:UR1-SDV</setSpec>
<setSpec>collection:IRSET-EHESP</setSpec>
<setSpec>collection:INRA</setSpec>
<setSpec>collection:AGREENIUM</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Long-term outcomes of the WEGENT trial on remission-maintenance for granulomatosis with polyangiitis or microscopic polyangiitis</title>
<creator>Puéchal, Xavier</creator>
<creator>Pagnoux, Christian</creator>
<creator>Perrodeau, Elodie</creator>
<creator>Hamidou, Mohamed</creator>
<creator>Boffa, Jean-Jacques</creator>
<creator>Kyndt, Xavier</creator>
<creator>Lifermann, François</creator>
<creator>Papo, Thomas</creator>
<creator>Merrien, Dominique</creator>
<creator>Smail, Amar</creator>
<creator>Delaval, Philippe</creator>
<creator>Hanrotel-Saliou, Catherine</creator>
<creator>Imbert, Bernard</creator>
<creator>Khouatra, Chahéra</creator>
<creator>Lambert, Marc</creator>
<creator>Leské, Charles</creator>
<creator>Ly, Kim</creator>
<creator>Pertuiset, Edouard</creator>
<creator>Roblot, Pascal</creator>
<creator>Ruivard, Marc</creator>
<creator>Subra, Jean-François</creator>
<creator>Viallard, Jean-François</creator>
<creator>Terrier, Benjamin</creator>
<creator>Cohen, Pascal</creator>
<creator>Mouthon, Luc</creator>
<creator>Le Jeunne, Claire</creator>
<creator>Ravaud, Philippe</creator>
<creator>Guillevin, Loïc</creator>
<contributor>Institut Cochin (UM3 (UMR 8104 / U1016)) ; Université Paris Descartes - Paris 5 (UPD5) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Centre National de la Recherche Scientifique (CNRS)</contributor>
<contributor>Service de médecine interne et centre de référence des maladies rares [CHU Cochin] ; Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Cochin [AP-HP]</contributor>
<contributor>Equipe 5 : METHODS - Méthodes de l’évaluation thérapeutique des maladies chroniques (CRESS - U1153) ; Université Paris Descartes - Paris 5 (UPD5) - Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A 1125)) ; Institut National de la Recherche Agronomique (INRA) - Université Sorbonne Paris Cité (USPC) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Institut National de la Recherche Agronomique (INRA) - Université Sorbonne Paris Cité (USPC) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Service de médecine interne [Nantes] ; Université de Nantes (UN) - Hôtel-Dieu - CHU Nantes</contributor>
<contributor>Remodelage et Reparation du Tissu Renal ; Université Pierre et Marie Curie - Paris 6 (UPMC) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Néphrologie ; Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Tenon [APHP]</contributor>
<contributor>Service de médecine interne et néphrologie ; CH Valenciennes</contributor>
<contributor>Service de Médecine Interne [Dax] ; Hôpital Dax</contributor>
<contributor>Hôpital Bichat - Claude Bernard ; Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Bichat - Claude Bernard [Paris] - Université Paris Diderot - Paris 7 (UPD7)</contributor>
<contributor>Centre Hospitalier Compiègne-Noyon</contributor>
<contributor>Service de Néphrologie - Médecine Interne ; CHU Amiens-Picardie - Hôpital Sud</contributor>
<contributor>Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; Université d'Angers (UA) - Université des Antilles et de la Guyane (UAG) - Université de Rennes 1 (UR1) - École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<contributor>Service de pneumologie ; CHU Pontchaillou [Rennes]</contributor>
<contributor>Immunologie et Pathologie (EA2216) ; Université de Brest (UBO) - IFR148</contributor>
<contributor>CHRU - Service de néphrologie, dialyse et transplantation rénale ; Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)</contributor>
<contributor>CHU Grenoble</contributor>
<contributor>Hôpital Louis-Pradel [Lyon] ; Université Claude Bernard Lyon 1 (UCBL) - Hospices Civils de Lyon - Hôpital Louis-Pradel</contributor>
<contributor>Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)</contributor>
<contributor>CH Cholet</contributor>
<contributor>CHU Limoges</contributor>
<contributor>Hopital Réné Dubos</contributor>
<contributor>Service de Médecine Interne ; CHU de Poitiers</contributor>
<contributor>CHU Estaing [Clermont-Ferrand]</contributor>
<contributor>Service de Néphrologie [Angers] ; Université d'Angers (UA) - CHU Angers</contributor>
<contributor>Service de Médecine Interne et Maladies Infectieuses [Pessac] ; CHU Bordeaux [Bordeaux] - Hôpital Haut-Lévêque</contributor>
<contributor>CHU Cochin [AP-HP]</contributor>
<contributor>Club Rhumatismes et Inflammation ; Club Rhumatismes et Inflammation</contributor>
<description>International audience</description>
<source>ISSN: 2326-5205</source>
<source>EISSN: 2326-5191</source>
<source>Arthritis & rheumatology</source>
<publisher>Wiley</publisher>
<identifier>hal-01217989</identifier>
<identifier>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01217989</identifier>
<identifier>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01217989/document</identifier>
<identifier>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01217989/file/Long-term%20outcomes%20of%20the%20WEGENT%20trial_accepted.pdf</identifier>
<source>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01217989</source>
<source>Arthritis & rheumatology, Wiley, 2016, 68 (3), pp.690-701. 〈10.1002/art.39450〉</source>
<identifier>DOI : 10.1002/art.39450</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1002/art.39450</relation>
<identifier>PUBMED : 26473755</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/26473755</relation>
<language>en</language>
<subject>[SDV] Life Sciences [q-bio]</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>OBJECTIVE: The WEGENT trial and other short-term studies suggested that azathioprine or methotrexate could effectively maintain granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) remission. Whether differences in relapse or adverse event rates would appear after discontinuation of those 2 maintenance regimens and longer follow-up remains unknown. METHODS: Long-term outcomes for the patients enrolled in the WEGENT trial were analyzed according to their randomization group. Parameters at trial entry were evaluated as potential prognostic factors for death, relapse or damage in multivariate models. RESULTS: Data were returned for 88.8% of the 126 original participants. Median [95% confidence interval] followup was 11.9 [11.3-12.5] years. For the azathioprine and methotrexate arms, respectively, the 10-year overall survival rates were 75.1% [64.8-86.9] and 79.9% [70.3-90.8] (P = 0.56), and relapse-free survival rates 26.3% [17.3-40.1] and 33.5% [23.5-47.7] (P = 0.29). No between-arm differences were observed for relapse, adverse events, damage, survival rates without severe side effects and survival rates without relapse and severe side effects. Considering only the 97 GPA patients, no between-arm survival differences were observed. Relapse-free survival was shorter for GPA than MPA patients but the multivariate analysis retained anti-PR3-ANCA-positivity, and not GPA, as being independently associated with relapse. CONCLUSION: This long-term analysis confirms that azathioprine and methotrexate are comparable options for maintaining GPA or MPA remission. Despite good overall survival, relapses, adverse events and damage remain matters of concern and further studies are needed to reduce them. </description>
<date>2016</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
